Molecular Therapy Journal Citation Rate 2026

ISSN 1525-0016 eISSN 1525-0024 Elsevier BV US

Q1 Quartile Top Tier

About Molecular Therapy
{# Self-contained "answer block": one dense, LLM-quotable paragraph stating every core fact with an explicit as-of year, server-rendered and unique per journal. This is the canonical fact statement — other sections add narrative, they do not restate these numbers. #}

Molecular Therapy (MT) is a peer-reviewed academic journal covering CAR-T cell therapy research and CRISPR and Genetic Engineering, published by Elsevier BV in US, catalogued under ISSN 1525-0016 (e-ISSN 1525-0024). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 5.62 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$3900 USD). OpenAlex records 22,906 works and 471,060 citations, with an h-index of 260.

Molecular Therapy Citation Rate 2026 — In Context

Molecular Therapy has a 2025 2-Year Citation Rate (OpenAlex) of 5.62, placing it in the Q1 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.

Molecular Therapy operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.

Researchers looking to publish in Molecular Therapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Molecular Therapy against similar journals in the field, use our journal comparison tool.

Submission Tips for Molecular Therapy
  • Budget $3900 for the Article Processing Charge. Check if your institution or funder covers OA fees.
  • This journal covers CAR-T cell therapy research, CRISPR and Genetic Engineering, RNA Interference and Gene Delivery. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Molecular Therapy Compares
Citation Rate vs Field Avg
-40%
Field avg: 9.36
APC vs Field Avg
-2%
Field avg: $3968

Compared against 48 journals in the same research areas.

ISSN (Print) 1525-0016
ISSN (Online) 1525-0024
Publisher Elsevier BV
Country United States
APC / Cost $3900 USD
In-depth profile & metrics

Molecular Therapy is published by Elsevier BV and based in United States. It runs on a subscription or hybrid model with an article-processing charge of USD 3900.

In our subject taxonomy, Molecular Therapy is classified under CAR-T cell therapy research, CRISPR and Genetic Engineering, RNA Interference and Gene Delivery and Viral Infectious Diseases and Gene Expression in Insects.

Molecular Therapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.

Its most recent citation rate stands at 5.617.

Research Areas
Links
Frequently Asked Questions about Molecular Therapy

Molecular Therapy does not hold a Clarivate (JCR) Impact Factor on JournalsHub. Its 2-year citation rate, computed from OpenAlex open citation data, is 5.617 — an open proxy for citation impact, not the licensed JCR Impact Factor.

No, Molecular Therapy is not an open access journal.

The Article Processing Charge (APC) for Molecular Therapy is $3900 USD.

Molecular Therapy is published by Elsevier BV.

Molecular Therapy shows strong legitimacy signals: it is indexed in OpenAlex. Indexing in recognised databases such as Scopus and DOAJ is a reliable indicator of a peer-reviewed, non-predatory journal, because predatory titles are typically excluded from them. Always confirm the journal's scope and editorial board fit your work before submitting.

The ISSN of Molecular Therapy is 1525-0016. Its electronic ISSN (eISSN) is 1525-0024.

Molecular Therapy sits in the Q1 quartile based on its latest impact factor of 5.62, ranked across all journals in our database.
Live Indexing Status
Updated April 2026

Track real-time indexing metrics to ensure this journal meets your academic requirements.

OpenAlex
Verified
DOAJ
Non-OA
Predatory Check
Clean
Citation Rate
5.617
2-Year Citation Rate (OpenAlex) · 2025
Historical Trend
Initial data points only
Citation Rate by Year
Year Value Source
2025 5.617 2-Year Mean Citedness (OpenAlex)

Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.

Research Highlights

Recently published high-impact papers in this journal:

Compare Journals

Compare Molecular Therapy against similar publications in its field:

Related Journals in Your Field

Metadata

Last updated: Apr 24, 2026

Updated by: openalex_bulk

OpenAlex ID: S51596929

Get weekly updates for CAR-T cell therapy research journals

Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google